Journal Article

Identification and Quantitation by High-Performance Liquid Chromatography of Mancozeb Following Derivatization by 1,2-Benzenedithiol*

Ikram Debbarh, Karine Titier, Evelyne Deridet and Nicholas Moore

in Journal of Analytical Toxicology

Volume 28, issue 1, pages 41-45
Published in print January 2004 | ISSN: 0146-4760
Published online January 2004 | e-ISSN: 1945-2403 | DOI: http://dx.doi.org/10.1093/jat/28.1.41
Identification and Quantitation by High-Performance Liquid Chromatography of Mancozeb Following Derivatization by 1,2-Benzenedithiol*

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

Ethylenebisdithiocarbamate (EBDC) fungicides are the most important class of organic fungicides and exhibit a high degree of carcinogenicity, mutagenicity, and neurotoxicity. For that reason, the safe application of these fungicides in practice requires a convenient method for their determination, applicable to biological fluids. We describe a high-performance liquid chromatography (HPLC) assay. After elimination of the metal which defines the product (maneb, mancozeb, zineb…) with EDTA, the resulting EBDC is derivatized with 1,2-benzenedithiol to yield a cyclocondensation product, 1,3-benzodithiole-2-thione, which can then be quantitated by reversed-phase HPLC at 365 nm using a µBondapak C18 column. The mobile phase was methanol/H20 (70:30, v/v). The assay was linear from 0.25 to 100 µg/mL. Within-and between-day precision and accuracy for this assay were better than 9% and 6%, respectively. The lower limits of detection and quantitation were estimated to be 0.1 and 0.25 µg/mL, respectively. This simple new method has been applied to determine mancozeb concentration in rat urine samples from urinary excretion studies.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.